FDA-cleared profile

Annalise Enterprise

Harrison-AI Medical Pty, Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.

Clinical role
Triage or notification support
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The device is not a rule-out tool, does not replace advanced stroke imaging or standard care, and excludes lacunar, brainstem, and venous infarcts from its acute-infarct definition.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Non-contrast axial brain CT with brain reconstruction kernel, slice thickness up to 5 mm, and up to 1,000 images.
  • Who uses it?Intended users: Trained clinicians qualified within their scope of practice to interpret brain CT studies.
  • What does the software produce?Output: Study-level notification for suspected acute infarct; no localizing output and no output that excludes infarct.
  • What is its most important limitation?Key limitation: The device is not a rule-out tool, does not replace advanced stroke imaging or standard care, and excludes lacunar, brainstem, and venous infarcts from its acute-infarct definition.

Clinical takeaway. Clinical role: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.

Evidence takeaway. Evidence from the reviewed source record: A retrospective study used consecutive cases from five U.S. hospital networks, with separate thin- and thick-slice cohorts and expert reference standards.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Triage or notification support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Non-contrast axial brain CT with brain reconstruction kernel, slice thickness up to 5 mm, and up to 1,000 images.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Study-level notification for suspected acute infarct; no localizing output and no output that excludes infarct.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adults aged 22 years and older.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Trained clinicians qualified within their scope of practice to interpret brain CT studies.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
The device is not a rule-out tool, does not replace advanced stroke imaging or standard care, and excludes lacunar, brainstem, and venous infarcts from its acute-infarct definition.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
A retrospective study used consecutive cases from five U.S. hospital networks, with separate thin- and thick-slice cohorts and expert reference standards.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
A retrospective study used consecutive cases from five U.S. hospital networks, with separate thin- and thick-slice cohorts and expert reference standards.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
86.1% (95% CI 82.4%-89.8%) at operating point 0.091176 in the thin-slice cohort.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported specificity
91.4% (95% CI 89.3%-93.4%) at operating point 0.091176 in the thin-slice cohort.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Sensitivity

86.1 percent

  • EndpointAcute-infarct triage sensitivity at operating point 0.091176
  • PopulationThin-slice non-contrast brain CT cohort
  • Tested versionAnnalise Enterprise submitted in K253818; build not stated

Specificity

91.4 percent

  • EndpointAcute-infarct triage specificity at operating point 0.091176
  • PopulationThin-slice non-contrast brain CT cohort
  • Tested versionAnnalise Enterprise submitted in K253818; build not stated

Annalise Enterprise acute-infarct regulatory performance study

  • DesignRetrospective multicenter standalone performance study
  • PopulationConsecutive cases from five U.S. hospital networks; 977 thin-slice and 1,050 thick-slice CT cases
  • Scopeexact submission
  • Tested versionAnnalise Enterprise submitted in K253818; build not stated
  • Samplen=2027
  • Sites5
  • IndependenceIndependence not established

K253818

Reference standard used two expert readers with third-reader adjudication; advanced imaging was available. Metrics above are thin-slice only.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast axial brain CT with brain reconstruction kernel, slice thickness up to 5 mm, and up to 1,000 images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K253818: Annalise Enterprise

  2. Routing

    Source context, not route validation: FDA labeling describes integration with PACS, RIS, or an order system for worklist notification.

    Scope: Exact FDA submission. Named platform examples do not establish a local compatibility commitment.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K253818: Annalise Enterprise

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Current hosting model was not established in the reviewed material.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: Study-level notification for suspected acute infarct; no localizing output and no output that excludes infarct.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K253818: Annalise Enterprise

  5. Viewer/worklist/report

    Unresolved route: Study-level notification for suspected acute infarct; no localizing output and no output that excludes infarct.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K253818: Annalise Enterprise

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
FDA labeling describes integration with PACS, RIS, or an order system for worklist notification.
  • Exact FDA submission
  • Checked 2026-09-05

Named platform examples do not establish a local compatibility commitment.

Security
Harrison.ai's data privacy FAQs state that data received for research and development arrives de-identified and encrypted, that a GDPR-aligned compliance baseline is maintained alongside local requirements such as the Australian Privacy Act, that technical, organisational and administrative safeguards protect personal data, and that patient images received from customers are not used to train AI models.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements. Entity bridge: the Harrison.ai privacy notice names 'Harrison-AI Medical Pty Ltd ABN 92 635 645 260' as a group entity, bridging the FDA applicant. The Harrison.ai Trust Centre rendered no readable content on 2026-10-26, so no certification claims were applied. Exact-release scope is not established.

Current vendor family context

Harrison.ai describes a broader CT-brain suite and an acute-infarct triage clearance announcement.

product family · checked 2026-09-05

Broader suite finding counts and workflows are not assumed for this exact acute-infarct configuration.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253818
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials candidates. Native-submission recall candidate snapshot was zero. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No scoped public price or procurement award was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Annalise Enterprise CT reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Harrison.ai's NTAP announcement concerns Annalise Obstructive Hydrocephalus, not this entry. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Current hosting model was not established in the reviewed material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    Current training/support commitments were not established.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K253818: Annalise Enterprise

    U.S. Food and Drug Administration - Published 2026-03-03 - Accessed 2026-09-05

    Scope: identity, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Harrison Comprehensive Care AI (CTB - acute infarct) model card (K253818)

    American College of Radiology - Published 2026-07-14 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Harrison.ai receives FDA clearance for acute infarct triage on non-contrast CT brain

    Harrison.ai - Published 2026-03-05 - Accessed 2026-09-05

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Harrison.ai: Data Privacy FAQs

    Harrison.ai - Published 2025-09-25 - Accessed 2026-10-27

    Scope: security

Research history

  1. K253818 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251195

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-01-27
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history